Post-ASH Second Annual Meeting. 21 December 1999, Grimbergen, Belgium [0.03%]
第九届ASH年会总结研讨会。1999年12月21日，比利时Grimbergen城
D Van Bockstaele
D Van Bockstaele
Design, production and evaluation of novel diagnostic and therapeutic reagents. 6-9 December 1999, La Jolla, CA, USA [0.03%]
新型诊断和治疗试剂的设计、生产和评估研讨会论文摘要集（美国加利福尼亚州拉乔拉，1999年12月6日－9日）
P J Hudson
P J Hudson
The timing of this meeting was indeed auspicious; the antibody engineers were able to celebrate the end of the decade and millennium with the launch of several dominant biotechnology products. Currently, over 30% of all new protein-based th...
Antibody engineering--IBC's Tenth International Conference. 6-9 December 1999, La Jolla, CA, USA [0.03%]
抗体工程学会第十九届国际会议(IBC) 1999年12月6~9日 美国加利福尼亚州拉乔拉市
P Carter
P Carter
This meeting covered emergent antibody technologies through preclinical and clinical development of antibodies to the latest clinical data with antibody drugs. On the technology front, human antibody phage libraries have increased in size a...
Gene-targeted therapeutic strategies--Royal Pharmaceutical Society Symposium. 9-10 December 1999, London, UK [0.03%]
基因治疗策略——皇家药学会研讨会主题报告。1999年12月9～10日，伦敦，英国
A Stephens
A Stephens
This meeting highlighted the approaches that are currently available for gene-targeted therapeutics. The meeting focused on two strategies: antigene and anti-message. Polyamides (an example of antigene targeting) have exhibited significant ...
European Society of Gene Therapy (ESGT) Seventh Meeting. 26-28 November 1999, Munich, Germany [0.03%]
欧洲基因治疗学会(ESGT)第七届年会. 1999年11月26日至28日,德国慕尼黑
M Anton,C Plank,E Rojo
M Anton
This meeting gave an excellent overview of the recent developments in gene therapy. Much research effort has focused on the improvement and de novo construction of gene vectors, on characterizing their mechanisms of action and on their inte...
Targets, targets everywhere--so where are the new antibacterial drugs? [0.03%]
目标、目标无处不在——但新的抗菌药物在哪里？
M J Pucci,T J Dougherty,J F Barrett
M J Pucci
NS-7 (Nippon Shinyaku) [0.03%]
NS-7(日本新药公司)
D L Small
D L Small
Nippon Shinyaku is developing NS-7, a sodium and calcium channel blocker, as a neuroprotectant for use following cerebral infarction [249336]. It entered phase I trials for the treatment of acute stage cerebrovascular disorders in 1997 [271...
J S Oxford
J S Oxford
Zanamivir, a neuraminidase inhibitor under license from Biota, has been developed and launched by Glaxo Wellcome for the treatment of influenza virus infection [277127]. While registered as drugs, neuraminidase inhibitors are technically va...
R Jones
R Jones
Rovelizumab is a humanized monoclonal leukointegrin antibody under development by ICOS as a potential treatment for multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke. ICOS announced the commencement of phase ...